Trial Profile

Doxapram Versus Placebo in Preterm Newborns: An International Double Blinded Multicenter Randomized Controlled Trial

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxapram (Primary) ; Doxapram (Primary)
Indications Apnoea; Hypoxic respiratory failure
Focus Adverse reactions
Acronyms Doxa TRIAL

Most Recent Events

18 Sep 2024 This trial is ongoing in Belgium according to European Clinical Trials Database record.
15 Mar 2024 Planned number of patients changed from 398 to 396.
27 Feb 2024 Planned End Date changed from 1 May 2030 to 1 May 2034.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com